Lutetium Lu 177 Vipivotide Tetraxetan
This page contains brief information about lutetium Lu 177 vipivotide tetraxetan and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Lutetium Lu 177 vipivotide tetraxetan is approved to treat:
- Prostate cancer that overproduces the PSMA protein and is castrate resistant (has not responded to treatments that lower testosterone levels). It is used in adults whose cancer is metastatic (has spread to other parts of the body) and has been treated with an androgen receptor blocker and taxane-based chemotherapy.
More About Lutetium Lu 177 Vipivotide Tetraxetan
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Clinical Trials Accepting Patients
Find Clinical Trials for Lutetium Lu 177 Vipivotide Tetraxetan - Check for trials from NCI's list of cancer clinical trials now accepting patients.